I004 insulin aspart biosimilar
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for I004 insulin aspart biosimilar, covering 2026-03-05 to 2026-03-05. Get the full timeline:
Most recent: Clinical Trial Update: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers [Phase 2, Phase 3]